anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PCT No. PCT/JP90/01313 Sec. 371 Date Jun. 9, 1992 Sec. 102(e) Date Jun. 9, 1992 PCT Filed Oct. 11, 1990 PCT Pub. No. WO91/05784 PCT Pub. Date May 2, 1991.Disclosed is a fused pyrimidine of the formula [I]    &lt;IMAGE&gt;  [I]  wherein R1, R2, and R3 are as defined in the specification, Y represents a linking group of the formula   &lt;IMAGE&gt;   wherein n is an integer of from 4 to 6,   &lt;IMAGE&gt;   N(A),OorS,  wherein A is a hydrogen atom or alkyl group; and Z represents a hydrogen atom, or other substituents; or Y and Z together represent an unsubstituted or substituted alkyl, alkenyl or arylalkyl group; or a 5- to 7-member heterocyclic ring which has a nitrogen atom, and further, an oxygen or sulfur atom as a hetero atom other than the nitrogen atom, being bonded via the nitrogen atom therein to the 4-position of the pyrimidine ring of the formula (I), a 5- to 7-member unsaturated heterocyclic ring which has 1 to 3 nitrogen atoms being bonded via the nitrogen atom therein to the 4-position of the pyrimidine ring of the formula (I), or a fused biheterocyclic ring constructed with 5- or 6-membered aromatic or non-aromatic rings, which has 1 to 3 nitrogen atoms in any position, being bonded via the nitrogen atom therein to the 4-position of the pyrimidine ring of the formula (I); and m is an integer of from 1 to 3; and a pharmaceutically acceptable acid addition salt thereof, as well as a process for producing same and a pharmaceutical preparation useful for a treatment of hypoxemia associated with respiratory diseases.
&lt;P&gt;PROBLEM TO BE SOLVED: To prevent the occurrence of air blocking at a leukocyte removing filter and also to improve a platelet collecting efficiency by reducing the number of platelets left within the leukocyte removing filter.  &lt;P&gt;SOLUTION: Sterile air that cause air blocking within a bag B3 for temporarily storing blood components is transferred to another disposable section B2. This allows to perform leukopheresis of platelets at any time without using a batch system, and also allows to pass plasma continuously after the platelets pass through the leukocyte removing filter F3. With such a configuration, the platelets left within the leukocyte removing filter is pushed out by the plasma to achieve an improvement in the platelet collecting efficiency. In addition, sterile air mixed into a bag for storing platelet after leukopheresis can be drawn out into the leukocyte removing filter without affecting the platelet collecting efficiency.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
Abstract A method of diagnosing and treating systemic Human Papilloma Virus (HPV) in particular &#34;viral colonies&#34; is disclosed. This method involves covering the skin of the feet and legs of a suspected infected human with topical applications selected from povidine iodine, potassium permanganate, aspirin, salicylic acid, natural salicin, lactic acid, alcohol, ether and any combination or mixture of them, and detecting &#34;HPV colony centres&#34; or lesions. The method of treatment of the detected HPV colony centres on the infected human includes topically administering any combination, mixture or percentage of aspirin, salicylic acid, natural salicin, paracetamol, phenacetin, whole natural grapefruit, povidine iodine and alcohol. These ingredients may be pureed, crushed, powered and or dissolved in water or grapefruit puree/juice, iodine or alcohol. The method optionally may contain the following further steps: a) initial intestinal cleansing with grapefruit seed extract(GSE) and /or Epsom salts, b) stretching and exercising the core infected area, c) i)treatment of the core infected area with firstly a topical treatment of any combination mixture or percentage of pureed whole potato and /or aloe vera stems mixed with either aspirin, salicylic acid, natural salicin, paracetamol, phenacetin, podivine iodine, alcohol, and/or epsom salts, then the core infected area is wrapped tightly in a sealed layer of plastic sheeting, and ii) secondly treating with another and final topical application consisting of any combinations, mixes and percentages of powdered Tobacco/nicotine, paracetamol, alcohol, Epsom salts, phenacetin, salicylic acid, salicin and/or aspirin. The method is supported or underpinned by a healthy lifestyle, a specified restrictive diet which avoids sugars and wheat products and certain vegetables and restricts the type and amounts of carbohydrates, a regime of daily specified supplements including salt, kelp, GSE, vitamin C, cod liver oil and Epsom salts and daily unprotected exposure to the sun.
PURPOSE: Oxazolidine derivative as an effective thrombocyte cohesion inhibitor is prepared. It is also useful in curing diseases caused from thromboembolism and cancer. CONSTITUTION: The reaction method counts on the reaction formula 1. &#34;Cyclized synthetic monomer&#34;, the intermediate product, is the following materials; phosgene class like diphosgene, triphosgene and thiophosgene, cyanogene class like bromocyanogene or chlorocyanogene, ester class like carbonic dimethylethyl or diphenyl ester, N,N-dimethyl formamide or so on. MN3 is methyl azide especially such as lithuim or sodium azide. TMSN3 means trimethylsilylazide.
PURPOSE:To provide a new compound AM5221 or its salt exhibiting excellent NGF-production promoting action and useful as an agent for the treatment of e.g. Alzheimer-type senile dementia, Huntington&#39;s chorea, diabetic peripheral nervous disorder, etc. CONSTITUTION:This new compound AM522l is a compound expressed by formula I (R is H or methyl) or its salt, e.g. AM5221A of formula II and AM5221B of formula III. The new compound AMl5221 of formula I or its salt can be produced by culturing a microbial, strain belonging to the genus Phialocephala and capable of producing the compound AM5221 and collecting the compound AM522l from the cultured product. The microbial, strain belonging to the genus Phialocephala and capable of producing the compound AMI5221 is Phialocephala humicola M5221 (FERM P-14279). The new compound AM522l of formula I or its salt is used as an active component of an agent for promoting the production of nerve growth factor. The compound is useful also as an agent for the treatment of peripheral. nerve injury, spinal injury and amyotrophic lateral sclerosis, an agent for improving cerebral metabolism or an agent for improving peripheral nerve disorder.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a gene therapy for treatment of degenerative arthritis.  &lt;P&gt;SOLUTION: The invention relates to the gene therapy treatment comprising preparation of expression vectors encoding one factor belonging to the transforming growth factor-beta (TGF-beta) superfamily which includes a DNA sequence linked to the promotor, transfection of the expression vectors into cultured connective tissue cells (fibroblasts, etc.), and injection of the transformed connective tissue cells into mammal host&#39;s arthritis articular cavity to promote regeneration of the connective tissue, hyaline cartilage or the like in the articular cavity. Partially defected cartilage model was made to stimulate degenerative arthritis of the knee joint. The partial cartilage defect treated with the cell-mediated gene therapy procedure was covered by newly formed hyaline cartilage which indicates that the cells survived and stimulated matrix formation in this area. Completely denuded cartilage areas were covered by fibrous collagen.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE: To obtain the subject new compound, having low irritancy to the skin or hair, good in tough thereon, excellent in foaming power and emulsification stability and useful for various detergents, emulsifying agents, conditioning agents, etc. CONSTITUTION: A multichain type amine derivative of formula I [R&lt;1&gt; is a (hydroxyl-substituted)straight-chain or branched chain 1-24C alkyl or alkenyl; R&lt;2&gt; is a (hydroxyl-substituted)straight-chain or branched chain 1-4C alkyl or alkenyl; X is a halogen], e.g. tris(2-hydroxy-4,4-dimethyl-4-azoniadodecyl)amine chloride. The compound of formula I is obtained by reacting an amine derivative of formula II with one or two or more halogenated hydrocarbons having different R&lt;2&gt; groups of the formula R&lt;2&gt; -X. Furthermore, the reaction is preferably carried out by reacting the compound of formula II with the halogenated hydrocarbon in an equiv. amount of 2-10 times based on three amino groups in the compound of formula II in the presence of, e.g. an inert solvent at 20-150 deg.C, preferably 60-120 deg.C.
The invention relates to the treatment of Parkinson patients with motor complications in need of Continuous Dopaminergic Stimulation. According to the invention a kit of pharmaceutical preparations is provided comprising levodopa and an AADC-inhibitor. Levodopa is applied via continuous subcutaneous infusion and Continuous Dopaminergic Stimulation is achieved by almost complete inhibition of the peripheral levodopa metabolism. To reach far-going blockage of levodopa metabolism, an AADC-inhibitor (e.g., benserazide, carbidopa) is given orally in a higher than normal dose and, as an indispensable prerequisite, the AADC-inhibitor has to be applied evenly distributed over the day, e.g., via a Modified Release formulation. In order to prevent levodopa conjugation over the COMT pathway, an oral COMT-inhibitor (e.g., opicapone) is also added. In addition, a drug-drug-interaction between the AADC-inhibitor and opicapone further increasing the activity of the former is likely to occur.The resulting effective inhibition of peripheral levodopa metabolism allows a marked reduction of the necessary (equivalent) levodopa (or prodrug) doses to 300 - 600 mg/day, which is, however, sufficient to reach high levodopa plasma levels of 1500 to 3000 ng/ml. The low daily levodopa dose is infused subcutaneously via minipump and is well-tolerated at the infusion site. The high steady-state levodopa plasma levels reached, allow effective Continuous Dopaminergic Stimulation-therapy for Parkinson&#39;s disease patients of any degree of severity. As additional benefit, the largely AADC-inhibition prevents the peripheral generation of dopamine and the cumbersome dopaminergic adverse effects (e.g., nausea, cardiovascular and gastro-intestinal adverse effects) are prevented.
PURPOSE:To provide a vaccine containing the antigen originated from the MCLS-type sanguis strain, and capable of effectively treating the human diseases (e.g. Kawasaki&#39;s disease, purpura, etc.) induced or deteriorated by MCL-type strain. CONSTITUTION:The objective vaccine contains (A) an antigen (preferably the antigen originated from the ciliated structure of the surface layer of cell wall) originated from the group comprising at least a part of the cell of a microbial strain belonging to Streptococcus sanguis having high pathogenic property, capable of decomposing raffinose and melibiose and differentiable from known sanguis strain, e.g. Streptococcus sanguis SSH83 (FERM P-7372), MCLS2 (FERM P-8169), etc., and its cultured product, and (B) a pharmacologically permissible carrier. A mammalian animal is immunized with the above antigen, and the antibody produced in the body of the animal is recovered. The antibody is effective for the treatment of human diseases induced and deteriorated by the MCLS- type bacterial strain.
The invention discloses a nucleic acid aptamer targeting esophageal squamous carcinoma cells, a screening method and application thereof. Based on the Cell-SELEX technology, KYSE150 cells are used as forward cells, HEEC cells are used as reverse cells, and nucleic acid aptamer EA1 which specifically binds to esophageal squamous carcinoma cells is obtained through repeated rounds of screening. The aptamer is small molecule single-stranded DNA, and the sequence is 5&#39;-ATGGCTTAGTGGCACGATTAGGTCAGGAATCG-3&#39;. Further in vitro and in vivo verification shows that the EA1 aptamer has extremely high affinity and specificity with esophageal squamous carcinoma target cells. The EA1 aptamer can be subjected to fluorescence modification to realize targeted imaging, and can also be used as a target molecule of a nano drug carrier to realize targeted delivery of an antitumor drug. The EA1 aptamer has the advantages of no immunogenicity, small molecular weight, chemical synthesis, good stability, easy modification and the like. The EA1 aptamer provides a high-efficiency and simple molecular tool for clinical accurate diagnosis, personalized treatment, drug targeting delivery and related basic research of occurrence, development and progress of esophageal cancer diseases, and has a wide application prospect.
PURPOSE:To provide the titled plaster capable of keeping the drug concentration in blood at a high level for a long period, by using mequitazine as an active component and a sticking base having a mequitazine-solubility of lower than a specific level at room temperature. CONSTITUTION:The objective long-acting anti-allergic plaster can be produced by using a sticking layer containing mequitazine [10-(3-quinuclidinemethyl) phenothiazine] and a sticking base and laminating the sticking layer to a substrate. The sticking base is selected to have a mequitazine-solubility of &lt;=10wt% at normal temperature. The substrate is preferably a light-shielding material, i.e. having a light transmission of &lt;=1% at 200-600nm wavelength measured by conventional ultraviolet and visible light absorption photometer. Since the solubility of mequitazine is &lt;=10t% at normal temperature, the barrierness of skin to mequitazine is lowered to provide high drug concentration in blood. Furthermore, the plaster has low skin irritation.
A skin care method and kit is disclosed that includes instructions for a dietary skin care regimen. The regimen includes a list of prohibited and allowed foods. The list of prohibited foods includes red meat, chocolate, eggs, confections, alcoholic beverages, shellfish, fried foods, and tomatoes. The list of allowed foods includes chicken, turkey, non-fried fish, vegetables, fruit other than a tomato, and olive oil as a salad dressing. The skin care kit further includes a compliance report including the list of prohibited and allowed foods with corresponding data input fields for each food in the list of prohibited and allowed foods. The user indicates an amount of each prohibited and allowed food item consumed by the user in the corresponding data input field. A compliance rating system is disclosed in which the total number of servings of prohibited and allowed foods consumed by the user determines the user&#39;s compliance level.
A biologically active cyclic synthetic peptide analog having an amino acid sequence similar to that of native epidermal growth factor between amino acids 32-48 is revealed. The peptide has been found to mimic certain biological activities of intact native epidermal growth factor (EGF). The EGF peptide analogs of the present invention include at least one sulfhydryl bond between two cysteines of the peptide containing block termini. The peptides comprise the end of the B-loop and the C-loop characteristic of the native form of the epidermal growth factor peptide. The biological activity of the peptide provides for methods of using the peptide as an agent in wound healing and also in cancer therapy. More particularly, the described peptides are used in cancer therapeutic applications and in the promotion of wound healing, especially burn wounds and peptic ulcer disease. Methods of preparing and using the described bioactive EGF analog peptides are also disclosed.  Both the D- and L- forms of the peptides&#39; amino acids are within the scope of the described biologically active peptides.
Compositions comprising outer membrane protein &#34;E&#34;, and peptides and oligope ptides thereof, of Moraxella catarrhalis are described. Additionally, nucleotide sequences encoding the protein, peptide, or oligope ptide are disclosed, as well as recombinant vectors cont aining these sequences. Protein, peptide, or oligopeptide can be produced from host  cell systems containing these recombinant vectors. Pept ides and oligopeptides can also be chemically synthesized. Disclosed are the uses  of the protein, peptides and oligopeptides as antigens for vaccine formulations, and as antigens in diagnostic immunoassays. The nucleo tide sequences are useful for constructing vectors for u se as vaccines, for insertions into attenuated bacteria in constructing a recom binant bacterial vaccume and for inserting into a viral vector in constructing a recombinant viral vaccine. Also described is the use of nucle otide sequences related to the gene encoding E as primer s and or probes in molecular diagnostic assays for the detection of M. catarrh alis.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medical information system allowing automatic and accurate acquisition and recording of medical information presented to a medical device or the like.  &lt;P&gt;SOLUTION: An information presentation part 1100 of the medical device 1000 is presented with the medical information such as character string information, graph information or the like. The information presentation part 1100 is stuck with a sheet type scanner 1, and the presented medical information is read. The read medical information is sent to a scanner control part 2, and is inputted to an information processing part 3 as two-dimensional image data. The information processing part 3 analyzes the inputted two-dimensional image data, and converts them into a prescribed data format, sends them to an information recording part 4 and makes the information recording part 4 record them.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
1,136,130. Thermosealable films. MONTECATINI SOCIETA GENERALE PER L&#39;INDUSTRIA MINERARIA E CHIMICA. 21 April, 1966 [27 April, 1965], No. 17487/66. Heading B2E. A thermosealable film for packing comprises an olefin polymeric film coated with a primer which is the reaction product of an amine with an oxyranic derivative in a molar ratio of from 1:0.01 to 1:0.99 respectively and a further layer of an acrylonitrile, vinylidene chloride, vinyl chloride, or vinyl acetate copolymer. The primer layer may consist of a reaction product of an oxyranic derivative with an alkyleneimine polymer or with a simple amino-compound such as ethylene diamine, diethylene triamine or tetra-ethylene pentamine. The oxyranic compound may be a polymeric reaction product of epichlorohydrin with a bis-phenol or with a glycidyl derivative such as a diglycidyl ether of diethylene glycol or N,N&#39;-diglycidyl piperazine. The substrate may be polypropylene film which has been previously bistretched. It may have been treated electrically and the film may be unstretched or stretched in only one direction. The primer layer may be coated on one or both sides of the film. Stretching may be carried out after coating. The primer may be applied as an emulsion or dispersion in water or in an organic solvent by spreading or by immersion at the film.
PROBLEM TO BE SOLVED: To obtain a sugar-coated tablet capable of decreasing the amount of a coated sugar, reducing the size and expressing an excellent tablet strength by applying a membrane comprising a polymer capable of being dissolved in both water and a lower alcohol to a sugar-coated tablet. SOLUTION: This sugar-coated tablet comprises a sugar-coated tablet whose surface is covered with a membrane comprising a polymer (preferably hydroxypropylcellulose or polyvinyl pyrrolidone) capable of being dissolved in both water and a lower alcohol (especially preferably ethanol). The weight ratio of the membrane comprising the polymer is preferably 0.1-2 wt.% based on the total amount of the sugar-coated tablet covered with the membrane. A bare tablet to be coated with a sugar is preferably prepared e.g. by mixing lactose, crystalline cellulose or the like as an excipient, if necessary, with a medicine and the like, and subsequently granulating the mixture. The sugar- coated tablet thereby permits to remarkably reduce the amount of the sugar coating, especially an intermediate layer, (by &lt;=40% based on the total amount of the bare tablet), or omit the sugar coating, to reduce the size of the tablet and to expect an excellent administration touch.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method of inhibiting metastasis or maintenance of various cancers.  &lt;P&gt;SOLUTION: The method includes a step for blocking a signaling of a chemokine receptor on a cell. In particular, the method makes use of the fact that certain trafficking of cancers depends upon identified proteins, which serves as markers. Additional methods of screenings are also provided. The metastasis is specific to organs (e.g., a lymph node, bone marrow or skin) or the cancer cells including breast, head and neck, malignant melanoma or prostate thereof.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
FIELD: organic chemistry. SUBSTANCE: synthesis is carried out by reaction of 5-bromo-2&#39;-chloro-2-aminobenzophenone with bromoacetyl bromide followed by treatment of bromoacetyl derivative with sodium iodide and 5-bromo-2-chloro-2-iodoacetylaminobenzophenone is obtained. The latter is heated with hydroxylamine sulfate followed by cyclization in the presence of hydrochloric acid and obtained 7-bromo-5-(o-chloro)phenyl-1,2-dihydro-3H-1,4-benzodiazepine-2- one-4-oxide is treated successively with acetic anhydride and alkali and then with succinic anhydride. The yield is 64%, m. p. is 200-205 C, empirical formula is C 19 H 14 BrClN 2 O 5 , toxicity LD 50  = 615 mg/kg. New compound in contrast to structural analog - phenazepam combines power soporofic, sedative and tranquilizing effects without accompanying by-side myorelaxant action. EFFECT: synthesis of new compound showing increased activity. 8 tbl
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing a distillate and an extract which comprise a vegetable ingredient having antibacterial properties and water retainability, uncolored and excellent in transparency and safety.  &lt;P&gt;SOLUTION: The method for producing the distillate comprises fractionally distilling a juice obtained by pressing leaves and stalks of Sasa kurilensis under reduced pressure at ≤70°C. The method for producing the distillate comprises adjusting the reduced pressure and the distilling temperature so that the distillate corresponds to ≤1 color number standard solution when examined by color number testing according to Gardner color number testing method. The method for producing an aqueous solution of Sasa kurilensis produces a distillate having pH3.5-pH4.8 without being washed with other water and having ≤60 Hz half-value width in measuring radiation isotope&lt;SP&gt;17&lt;/SP&gt;O by NMR (Nuclear Magnetic Resonance). The method for producing the Sasa kurilensis extract comprises mixing and dissolving the remaining solution of distillation in the distillate and filtrating. Cosmetics having antibacterial properties and water retainability, almost clear, odorless and excellent in safety are obtained by compounding the distillate or the extract.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
An aqs. product for the care of the mouth and teeth contng. Bacillus subtilis protease. Compared with fungal or pancreatic enzymes, the above protease is toxicologically innocuous and more stable in toothpastes. Inhibits the formn. of hard or soft deposits on the teeth and prevents parodontal diseases. The product, e.g. a toothpaste, contains the usual adjuvants and excipients together with Bacillus subtilis protease (0.2-5 Anson units/g) in an amount of 0.05-10% by wt., pref. 0.25-2.5%. Optionally, a fluorine cpd., pref. water-sol., may be added in an amount is not &gt; 2% by wt.